Giovanni Abbadessa
Company: Sanofi
Job title: Global Head of Oncology Early Development, & Global Project Head, peg-IL-2 (THOR-707/ SAR444245)
Seminars:
Development of SAR444245 (THOR-707) & Considerations for NK Cells & Immune Engager Combinations 1:00 pm
day: Day Two
Group Panel Discussion: Side Effects – Mitigating Against Hypotension + Fever With Immune-Stimulating Agents (NK Cell Engagers, PD-1s, Cytokines, T-Cell Engagers) = Cytokine Release Syndrome (CRS)? 11:30 am
What are the differences between the symtoms and the tests Uncover the implications for patients and regulatory bodies Examine the Implications for CAR-T Could this redefine CRS?Read more
day: Day Two